NVAXNOVAVAX INC

Nasdaq novavax.com


$ 8.89 $ 4.42 (98.88 %)    

Friday, 10-May-2024 15:59:55 EDT
QQQ $ 441.71 $ -1.21 (-0.27 %)
DIA $ 395.04 $ 1.04 (0.26 %)
SPY $ 520.76 $ 0.59 (0.11 %)
TLT $ 90.14 $ -0.49 (-0.54 %)
GLD $ 218.73 $ 1.78 (0.82 %)
$ 8.88
$ 9.79
$ 0.00 x 0
$ 0.00 x 0
$ 8.61 - $ 11.00
$ 3.53 - $ 10.30
4,533,199
na
625.42M
$ 0.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-11-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-14-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 02-27-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 b-of-a-securities-upgrades-novavax-to-neutral-raises-price-target-to-12

B of A Securities analyst Alec Stranahan upgrades Novavax (NASDAQ:NVAX) from Underperform to Neutral and raises the price ta...

 stocks-pause-on-dismal-consumer-confidence-yields-dollar-rise-as-inflation-expectations-kick-higher-bitcoin-sinks-whats-driving-markets-friday-corrected

Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.

Core News & Articles

NVDAALCCNVAXTSLATSMMARAAAPLINTCBADJTData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 novavax-exec-says-prioritizing-improvements-to-long-term-supply-chain-efficiency-including-exploring-sale-of-czech-republic-manufacturing-facility-fy24-revenue-guidance-reflects-advanced-purchase-agreements-expected-dose-delivery-schedules-of-15m-250m-revenue-guidance-reflects-non-advanced-purchase-agreements-related-revenue-of-250m-350m

- Conf Call

 novavax-exec-says-have-decided-in-consultation-with-fda-to-seek-emergency-use-authorization-for-updated-covid-vaccine-targeting-jn1-variant-reduced-workforce-by-30-compared-to-q1-2023

- Conf Call

 novavax-exec-says-intend-to-have-covid-vaccine-at-distribution-centers-in-the-us-no-later-than-mid-august-intend-to-have-covid-vaccine-ready-for-the-fall-season-in-early-september-pending-fda-approval-will-have-improved-retail-access-for-the-season-for-cos-covid-vaccine

- Conf Call

 novavax-exec-says-now-anticipate-data-readouts-for-both-novavaxs-combination-covid-flu-shot-and-standalone-flu-vaccine-in-mid-2025-expect-royalties-milestones-from-deal-with-sanofi-to-exceed-value-of-what-cos-own-efforts-might-have-yielded-has-been-challenging-for-co-to-transition-from-being-an-innovator-to-being-a-commercial-business

- Conf Call

 novavax-exec-says-expect-royalties-milestones-from-deal-with-sanofi-to-exceed-value-of-what-cos-own-efforts-might-have-yielded

- Conf Call

Core News & Articles
Market-Moving News for May 10th
05/10/2024 12:41:27

ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering ...

 some-breather-for-novavaxs-covid-19-vaccine-inks-multibillion-dollar-deal-with-sanofi-and-erases-doubts-about-its-going-concern

Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront pay...

 us-stocks-set-to-end-week-strong-with-sp-500-eyeing-break-above-late-march-peak-analyst-says-hes-still-a-buy-in-may-amid-this-positive-signal

U.S. stocks are on track to finish the week on a high, with the index futures pointing to a higher opening on Friday.

 novavax-updates-2024-guidance-expects-combined-revenue-and-sanofi-agreement-payments-of-970m-117b-prior-800m-1b-and-combined-rd-and-sga-of-700m-750m-prior-700m-800m

Financial Framework Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives:...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION